Memory Health Awarded UK Patent as Alzheimer’s Treatment

Memory Health Awarded UK Patent as Alzheimer’s Treatment

February 13, 2020

Memory Health Awarded UK Patent As Alzheimer's Treatment

The United Kingdom has awarded Memory Health a patent for a proprietary brain health supplement developed to prevent and treat neurodegenerative disease.

Also called Memory Health, the all-natural nutritional supplement is made especially for Alzheimer’s disease (AD) and dementia patients. The company is the sole licensee for the formulation patented by the United Kingdom Patent Office.

“This is a major milestone in the endless quest to prevent and treat neurodegenerative diseases like dementia and Alzheimer’s disease,” said Frederic J. Jouhet, founder of Michigan-based Memory Health, in a press release. “We’re so happy to be able to provide hope for current sufferers and their families, as well as a solution to prevent future disease, using a scientifically designed and scientifically tested nutritional supplement,” he said.

Developed by European investigators who for decades studied the role of nutrition in brain health, the Memory Health formula was ultimately tested in three clinical trials on patients with healthy brains and on those with AD.

Published in the April 2018 issue of the Journal of Alzheimer’s Disease , trial results showed improvement in memory and brain health for all who used the formula. Caregivers also reported that AD patients taking Memory Health experienced enhanced memory, vision and overall quality of life.

“The inventors have found that the macular carotenoids such as a mixture of meso-zeaxanthin, lutein and zeaxanthin, or omega-3 fatty acids, given separately, have no effect individually on the progression of dementia, but when given together are remarkably and surprisingly effective in halting or retarding the progression of the disease, and improving cognitive function,” according to the patent summary.

A growing body of scientific evidence suggests that enrichment of certain nutritional brain compounds may reduce the risk of AD. The study, “Nutritional Intervention to Prevent Alzheimer’s Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined” and published in JAD, investigated the effects of supplemental xanthophyll carotenoids plus omega-3 fatty acids on disease progression in patients with AD.

The report states that evidence suggests positive outcomes for AD patients who consumed a combination of xanthophyll carotenoids plus fish oil, but that further study is needed. The oral supplement works by delivering essential nutrients in the form of antioxidants and anti-inflammatories directly to the brain. The product’s natural ingredients include carotenoids, omega-3s and natural vitamin E.

“This patent granted in the United Kingdom to a group of relentless researchers in the space of nutrition for the eyes and the brain is the first ray of hope in the fight for better brain health,” said Jouhet. “This product gives us a roadmap to determine the exact nutritional deficiencies that cause degenerative brain conditions like dementia and Alzheimer’s. And it provides a scientifically designed supplement to remedy that shortage of nutrients in our daily diets.”

Memory Health has been available in the U.K. for three years, and was introduced in the United States two years ago, the company’s managing partner Ed Shehab told Alzheimer’s News Today. The formulation’s patent as a treatment sets the product apart from numerous other supplements commercially available. A U.S. patent is pending.

“This is real science proving real results for real people,” said Shehab. “This second patent continues to validate the true efficacy of our product versus so-called industry leaders with less science but larger advertising budgets. Everybody claims to have success, but our success has been proven by clinical research trials, published in highly respected medical journals and further validated with this latest patent.”

Mary Chapman

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”

Fact Checked By:

Ana de Barros, PhD

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.



Leave a comment

Comments will be approved before showing up.